AUG 14, 2026 · PHASE 3 TRIAL
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
ClinicalTrials.gov
This is a Phase 3 trial registration with no results reported; the study is actively recruiting and outcome data are not yet available.
Reported
Planned enrollment530
PhasePhase 3
Primary outcome measureOverall Survival